Immunotherapy plus chemo before surgery for HR+/HER2- breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if this treatment can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your breast cancer is hormone receptor positive (HR+) and HER2 negative (confirmed by biopsy).
- Your tumor is high grade (grade 3) or grade 2 with low ER expression (1-10%).
- Your cancer is at a certain stage (T1c-T2cN1-2 or T3-4cN0-2, M0) and has not spread to distant sites.
- You have not had any prior treatment for this breast cancer (like chemo, hormone therapy, or surgery, except a biopsy).
- You are generally healthy with no major heart, lung, liver, kidney, or immune problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery for early-stage triple-negative breast cancer. It aims to see if the treatment shrinks the tumor enough to make surgery more effective.
This trial tests a new drug (QL1706) combined with hormone therapy for breast cancer that did not shrink enough with initial chemotherapy. The goal is to see if this combination can improve treatment response before surgery.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery for cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether the drug QL1706, given before surgery, can help treat hormone receptor positive and HER2-negative breast cancer. It is for people who have not yet had cancer spread to other parts of the body.
This trial tests a new combination of immunotherapy drugs plus radiation and chemotherapy for people with large, hard-to-treat head and neck cancer that hasn't spread far. It aims to see if this approach can shrink tumors and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.